Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets

- Real-world claims data were used to compare CVD risk across LDL-P and LDL-C thresholds.
- The risk of a CVD event increased by 4% for each 100 nmol/L increase in LDL-P level.
- Patients with LDL-P <1000 nmol/L received more aggressive lipid-lowering therapy than patients with LDL-C <100 mg/dL.
- These differences in lipids and therapeutic management were associated with a reduction in CVD events in the LDL-P cohort.

ObjectivesPrevious research suggests that LDL particle number (LDL-P) may be a better tool than LDL cholesterol (LDL-C) to guide LDL-lowering therapy. Using real-world data, this study has two objectives: [1] to determine the incidence of CHD across LDL-P thresholds; and [2] to compare CHD/stroke events among patients achieving comparably low LDL-P or LDL-C levels.MethodsA claims analysis was conducted among high-risk patients identified from the HealthCore Integrated Research DatabaseSM. The impact of LDL levels on risk was compared across cohorts who achieved LDL-P <1000 nmol/L or LDL-C <100 mg/dL. Cohorts were matched to balance demographic and comorbidity differences.ResultsAmong 15,569 patients with LDL-P measurements, the risk of a CHD event increased by 4% for each 100 nmol/L increase in LDL-P level (HR 1.04; 95% CI 1.02-1.05, p < .0001). The comparative analysis included 2,094 matched patients with ≥12 months of follow-up, 1,242 with ≥24 months and 705 with ≥36 months. At all time periods, patients undergoing LDL-P measurement were more likely to receive intensive lipid-lowering therapy and had a lower risk of CHD/stroke than those in the LDL-C cohort (HR: 0.76; 95% CI: 0.61-0.96; at 12 months).ConclusionsIn this real-world sample of commercially insured patients, higher LDL-P levels were associated with increased CHD risk. Moreover, high-risk patients who achieved LDL-P <1000 nmol/L received more aggressive lipid-lowering therapy than patients achieving LDL-C <100 mg/dL, and these differences in lipids and therapeutic management were associated with a reduction in CHD/stroke events over 12, 24 and 36 months follow-up.